Danaher 2026 Bioprocessing Growth Outlook: Demand Signals and Investment Cycle

Danaher bioprocessing: what the current demand and backlog signals suggest for 2026 growth

Danaher’s 2026 bioprocessing outlook is being supported by two linked “signals”: (1) demand from biologics manufacturing and (2) backlog / demand visibility in the form of equipment order momentum and funnel activity. Management characterizes the current demand backdrop as strong, and the equipment “book” as improving in a way that they expect to translate into a multi-year investment cycle.

---

1) Demand signal: commercial biologic drug production is strong; consumables are the near-term beneficiary

Consumables demand: high single-digit bioprocessing growth in Q1

Danaher reports that core revenue in bioprocessing grew high single digits in Q1. ¹

They also attribute this to strong underlying commercial biologic drug production, which drives strength in consumables. ²
Additionally, they cite notable strength in China within the bioprocessing consumables demand environment. ¹

Underlying “why” for sustained demand: robust mAb production and continued biologics approvals

Danaher says monoclonal antibody production remains robust and is expected to continue growing at historical or better rates, driven by new molecules, biosimilars, and increased utilization of existing therapies. ³
They further support demand durability by noting a sustained pace of new biologic drug approvals in Q1 2026, building on a robust 2025 approval level. ³

Implication for 2026: With consumables tied to running/production activity, these comments suggest demand is not just “stabilizing,” but remains anchored by the ongoing expansion of commercial biologics output. ²³

---

2) Backlog signal: equipment order momentum is improving sharply (and is explicitly a 2026/“multi-year cycle” underpin)

Equipment orders: >30% year-over-year growth and “early stages of a multiyear investment cycle”

Management highlights that in Q1 equipment declined modestly, but they were encouraged to see orders growth of more than 30% year-over-year, calling it the first quarter of YoY equipment order growth in nearly 2 years. ¹
They also state they are “encouraged by improved trends in bioprocessing equipment” and believe they are in the early stages of a multiyear investment cycle. ³

Funnel activity + equipment backlog dynamics: brownfield now, greenfield later

Danaher links demand visibility to funnel and project pipeline activity, saying funnel activity continues to be robust and that equipment orders growth is supported by two dimensions, including underinvestment in industry capacity for the last 2 years. ⁴
They describe investment behavior as flowing first through brownfield projects, with larger greenfield investments expected to follow. ³⁴

They also state reshoring is a second dimension supporting activity (including “brownfield expansions” tied to reshoring dialogue/order activity). ⁵⁴

Implication for 2026: Even though reported Q1 equipment revenue was only modestly down, the >30% YoY order growth and robust funnel activity suggest backlog is building in a way that should support later-period equipment conversion during 2026 and beyond. ¹⁴

---

3) How this maps to 2026 growth expectations: Danaher expects bioprocessing to remain a key growth engine, but acknowledges it needs to accelerate vs current run-rate

Management’s stated need for “better-than” high single-digit bioprocessing growth to reach the top end of overall expectations

When discussing what would be required to reach higher end points in their 2026 core growth planning, Danaher explicitly says:

• “bioprocessing… we probably need to see it a little bit better than the high single-digit growth” ⁶
• and they specifically reference needing to accelerate consumables and get equipment growth going further. ⁶

This is important because it frames the backlog/demand signals as positive—but not yet sufficient on their own to guarantee that bioprocessing automatically achieves the upper growth trajectory without further translation from orders/funnel into consumables + equipment execution. ⁶

Company-wide 2026 framing: core revenue growth guide unchanged (3% to 6%)

Danaher states there is no change to expectations of core revenue growth in the 3% to 6% range for full-year 2026. ⁷
They also reaffirm growth progression acceleration throughout the year. ⁷

Implication for 2026: The backlog signal (orders) and demand signal (consumables/production) are consistent with management’s belief that the business can strengthen through the year, while still requiring continued conversion into equipment and stronger consumables acceleration for top-end outcomes. ¹⁷⁶

---

4) The clearest “current signals” to watch for 2026 conversion (based on what management emphasized)

1. Sustained equipment order growth / funnel strength

   • Q1: >30% YoY equipment order growth and robust funnel activity are key indicators. ¹⁴

2. Acceleration in consumables tied to commercial therapy production

   • Q1: bioprocessing high single-digit growth and consumables strength driven by commercial biologic drug production. ²¹

3. Progression from brownfield to greenfield over a multiyear cycle

   • Management expects brownfield activity to appear first and larger greenfield investment to follow, consistent with evolving capacity needs and pipeline expansion. ³⁴

4. Regional demand visibility, especially China

   • Bioprocessing consumables show notable strength in China, and China bioprocessing is described as encouraging with double-digit growth in the bioprocessing business in Q1. ¹⁸

---

Bottom line (what the signals indicate for 2026 bioprocessing growth trends)

• Demand appears strong and durable: management points to robust commercial biologic production and sustained biologic approvals, producing high single-digit bioprocessing growth in Q1 with consumables as the near-term beneficiary. ²³¹
• Backlog visibility is improving materially: Q1 shows >30% YoY equipment order growth and management links this to an early multiyear investment cycle, with funnel activity supporting continued capacity expansion. ¹³⁴
• But for the “best” 2026 growth outcome, Danaher implies further acceleration is needed: they explicitly state bioprocessing may need to be a little bit better than high single-digit growth, including faster consumables acceleration and stronger equipment growth as the year progresses. ⁶

In other words, the demand + backlog signals point to a constructive 2026 bioprocessing trajectory, with the key growth swing-factor being how quickly equipment orders and funnel activity translate into equipment revenue and continued consumables acceleration during 2026. ¹³⁶